Compound Contains Two Or More C(=o)o Groups Patents (Class 514/547)
-
Publication number: 20140316000Abstract: Composition of allomones and kairomones derived from the uropygeal gland of ducks and chickens are described, as well as methods to treat Arachnids.Type: ApplicationFiled: July 1, 2014Publication date: October 23, 2014Inventor: Patrick Pageat
-
Publication number: 20140310827Abstract: A novel microalgal strain whose lipid production has been enhanced compared to the wild type. The lipid content produced by the microalgae is particularly rich in neutral lipids. The use of the microalgal strain and the lipids are also described.Type: ApplicationFiled: August 16, 2012Publication date: October 16, 2014Applicant: INSTITUT FRANCAIS DE RECHERCHE POUR L'EXPLOITATION DE LA MER (IFREMER)Inventors: Nolween Dubois, Jean-Paul Cadoret, Gael Bougaran, Catherine Rouxel, Sophie Doulin
-
Publication number: 20140303249Abstract: Anhydrous agents for topical application, comprising one or more C1-C4 alkyl esters of lactic acid, malic acid, tartaric acid or citric acid and physiologically acceptable excipients, are described for the treatment of nail disorders caused by mycoses and for nail care. The agents according to the invention are also suitable in veterinary medicine for treating fungal infections of the hooves, claws and talons of pets and farm animals and wild animals living in captivity.Type: ApplicationFiled: June 11, 2014Publication date: October 9, 2014Inventor: Hans Meyer
-
Publication number: 20140302156Abstract: The invention concerns a rigid shaped article essentially consisting of a plurality of mutually adhering grains of sand provided with a coating consisting of wax, for the elimination or relief of itching. In a particular embodiment of the invention, the wax essentially consists of beeswax.Type: ApplicationFiled: August 25, 2011Publication date: October 9, 2014Inventor: Norbert Beermann
-
Patent number: 8853269Abstract: Compositions and methods for the treatment of intestinal infections. Compositions that include a liquid crystal mixture of an antimicrobial glycerol fatty acid ester and a polyhydric alcohol inhibit the growth of numerous deleterious intestinal pathogenic bacteria, including C. difficile. C. difficile is the causative agent in an increasing number of antibiotic-resistant bacterial infections. The formulations may be administered orally as capsules or soft gels, or alternatively as a enema, colonic, or rectal suppository. When combined with a probiotic supplement, the liquid crystal combinations reported here are able to treat an intestinal bacterial infection effectively and safely, thus promoting general intestinal health.Type: GrantFiled: February 4, 2011Date of Patent: October 7, 2014Assignee: Copperhead Chemical Company Inc.Inventors: James David Mosbaugh, Richard Peter Curtie Calvert, Eric J. Brooks
-
Publication number: 20140296338Abstract: An object of the present invention is to provide a drug that contains a compound for inhibiting neutral lipid accumulation in cardiovascular tissue or cells and has an excellent prophylactic or therapeutic effect on cardiovascular complications of diabetes. The present invention relates to a prophylactic and/or therapeutic agent for cardiovascular complications of diabetes, the agent containing a compound (preferably a medium-chain fatty acid and/or a medium-chain triglyceride) for inhibiting neutral lipid accumulation.Type: ApplicationFiled: August 27, 2012Publication date: October 2, 2014Inventors: Ken-ichi Hirano, Yoko Yasui, Yoshihiko Ikeda, Mitsutoshi Setou, Nobuhiro Zaima
-
Publication number: 20140294782Abstract: Disclosed are membrane-anchored polynucleotides, and compositions comprising the membrane-anchored polynucleotides. Also disclosed are the processes for the synthesis of these compounds, compositions comprising such compounds, and the use of such compounds and compositions in research and therapeutic applications.Type: ApplicationFiled: November 1, 2012Publication date: October 2, 2014Inventors: Zev Jordan Gartner, Nicholas Scott Selden, Michael E. Todhunter, Samantha Isabel Liang, Robert Joseph Weber, Noel Youngho Jee, Jennifer S. Liu
-
Publication number: 20140288144Abstract: A compound of formula (I): R?—O-A-O—R??, in which R? and R? are a hydrogen atom or a monovalent radical of formula (IIa), or a monovalent radical of formula (IIb), it being understood that at least one of the radicals R? or R? is not a hydrogen atom and that, when none of the radicals R? and R? is a hydrogen atom, R? and R? are identical, and in which A is a divalent radical of formula (III): —CH(X1)-[C(X2)(X3)]p-CH(X4) in which X1, X2, X3 and X4 are identical or different and are either a hydrogen atom or a methyl radical or an ethyl radical, and p is an integer greater than or equal to 1 and less than or equal to 6. Also the method for preparing the compound of formula (I) and to the use thereof in cosmetics and as a drug.Type: ApplicationFiled: October 12, 2012Publication date: September 25, 2014Applicant: Societe D'Exploitation de Produits Pour Les Industries Chimiques SeppicInventors: Sandy Dumont, Jerome Guilbot, Stephanie Garcel, Laetitia Cattuzzato
-
Publication number: 20140284245Abstract: Pharmaceutical compositions and dosage forms of dimethyl fumarate containing low levels of certain impurities are disclosed.Type: ApplicationFiled: March 24, 2014Publication date: September 25, 2014Applicant: XenoPort, Inc.Inventors: Sami Karaborni, Wei Chen, Suresh Kumar Manthati
-
Publication number: 20140287006Abstract: The present invention relates to degradation-stabilised, biocompatible collagen matrices which are distinguished in particular by the fact that they contain soluble collagen and peptide constituents, to processes for the preparation of such collagen matrices, which processes include in particular chemical crosslinking with an epoxy-functional crosslinking agent, and to the use of the collagen matrices according to the invention as a cosmetic or pharmaceutical agent, in particular for topical use, and as a wound treatment agent, as an implant or as a haemostatic agent in humans or animals, and as a scaffold for cell population in the biotechnology, basic research and tissue engineering field.Type: ApplicationFiled: March 28, 2014Publication date: September 25, 2014Inventors: Ralf Malessa, Anja Kassner
-
Publication number: 20140286886Abstract: The present invention relates to a cosmetic make-up or care composition comprising an oily phase comprising at least one liquid polyester obtained by condensation of unsaturated fatty acid dimer and/or trimer and diol, said composition being free from lipophilic gelling agent or comprising at the most 10 wt. % thereof, relative to the weight of the composition. The present invention also relates to a method of make-up of the face and body comprising the use of said composition.Type: ApplicationFiled: April 14, 2014Publication date: September 25, 2014Applicant: L'OREALInventors: Claudia BARBA, Audrey Ricard
-
Publication number: 20140288142Abstract: The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metobolisms dysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet adhesion, for treating pathological conditions resulting from abnormal cell proliferation, vascular diseases. The invention also relates to compositions comprising at least one nitric oxide releasing compounds of the invention and composition comprising at least one nitric oxide releasing compounds according to the invention and at least one 15 therapeutic agent.Type: ApplicationFiled: June 9, 2014Publication date: September 25, 2014Inventors: Nicoletta ALMIRANTE, Stefano BIONDI, Ennio ONGINI, Laura STORONI, Alessia NICOTRA
-
Publication number: 20140288175Abstract: A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.Type: ApplicationFiled: March 14, 2014Publication date: September 25, 2014Applicant: Baylor Research InstituteInventor: Charles R. ROE
-
Publication number: 20140275251Abstract: [Problem] Provision of a composition for external use on skin that is safe to use and has an anti-inflammatory and anti-allergic actions. [Solution] A composition for external use on skin in the treatment of inflammatory disease which comprises dihomo-?-linolenic acid (DGLA) as an active ingredient. The DGLA is preferably contained as a glyceride, a phospholipid, or an alkyl ester. The composition for external use contains DGLA in an amount of 0.1-50 wt %.Type: ApplicationFiled: May 11, 2012Publication date: September 18, 2014Applicant: NIPPON SUISAN KAISHA, LTD.Inventors: Jiro Takeo, Hiroyuki Kawahara
-
Publication number: 20140275250Abstract: Methods of therapeutic treatment using monomethyl fumarate are disclosed.Type: ApplicationFiled: August 22, 2013Publication date: September 18, 2014Applicant: XenoPort, Inc.Inventor: Kenneth C. Cundy
-
Publication number: 20140275048Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Alkermes Pharma Ireland LimitedInventors: Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame
-
Publication number: 20140274957Abstract: The present invention includes compositions and methods for treating certain conditions, the composition comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is used to treat at least one of autonomic dysfunctions or vascular diseases.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Inventor: Diana Driscoll
-
Patent number: 8835495Abstract: The present invention relates to an association of active ingredients. More specifically: to an association of cyclobenzaprine and aceclofenac. Additionally, the present invention is also related to the use of aceclofenac and cyclobenzaprine, in association for the preparation of a medicine useful in the treatment of painful muscular diseases, as well as to a method of treatment of painful muscular diseases using an association of aceclofenac and cyclobenzaprine.Type: GrantFiled: June 6, 2007Date of Patent: September 16, 2014Assignee: Incrementha P, D & I Pesquisa, Desenvolvimento e Inovacao de Farmacos e Medicamentos LtdaInventors: Dante Alario Júnior, Julio Cesar Gagliardi
-
Patent number: 8835496Abstract: The present invention relates to a human beta-defensin inducing agent that comprises at least one fat or oil of an essential fatty acid triglyceride or a derivative thereof as the main active ingredient. It also relates to cosmetic, dermatological and pharmacological formulations comprising the at least one fat or oil.Type: GrantFiled: November 9, 2010Date of Patent: September 16, 2014Assignee: Croda International PLCInventors: Anthony Vincent Rawlings, Debra Louise Jones
-
Patent number: 8821878Abstract: The disclosure features methods of making compositions that include a human lipid. The methods can include: obtaining whole human milk; separating the milk into a cream portion and a skim portion; processing the cream portion; and pasteurizing the processed cream portion.Type: GrantFiled: January 14, 2013Date of Patent: September 2, 2014Assignee: Prolacta Bioscience, Inc.Inventors: Elena M. Medo, Scott Eaker
-
Publication number: 20140243410Abstract: A method is provided for treating a subject in need of medication as an adjunct to elective surgery, comprising administration of a ketogenic material sufficient to produce a physiologically acceptable ketosis in the patient. Preferably the surgery is selected from the groups consisting of removal or section of tumours, removal of redundant organs such as lymph nodes and appendix, open heart surgery, cosmetic surgery, joint and bone surgery.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Applicant: BTG International LimitedInventors: Keith Frank Martin, David John Heal
-
Publication number: 20140243411Abstract: The present invention relates to topical trisodium diethylenetriamine pentaacetic acid (DTPA) prodrug formulations and methods of using the same.Type: ApplicationFiled: October 19, 2012Publication date: August 28, 2014Inventors: Michael Jay, Russell Mumper, Yong Zhang
-
Publication number: 20140221330Abstract: An objective of the present invention is to provide a novel NDM (New Delhi metallo-?-lactamase) inhibitor that functions as a drug for restoring the antibacterial activity of ?-lactam antibiotics that have been inactivated as a result of decomposition by NDM.Type: ApplicationFiled: July 26, 2012Publication date: August 7, 2014Inventors: Akihiro Morinaka, Kazunori Maebashi, Takashi Ida, Muneo Hikida, Mototsugu Yamada, Takao Abe
-
Publication number: 20140221482Abstract: Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.Type: ApplicationFiled: December 13, 2013Publication date: August 7, 2014Applicants: Baylor Research Institute at Dallas, National Institute of Health and Medical ResearchInventors: Fanny Mochel, Raphael Schiffmann
-
Publication number: 20140221483Abstract: A GIP-increase inhibitor, which may be utilized for producing a medicine, a food, or the like, is provided. The GIP-increase inhibitor contains triacylglycerol in which ?-linolenic acid accounts for 10% by mass or more of the constituent fatty acid, as an effective ingredient.Type: ApplicationFiled: September 14, 2012Publication date: August 7, 2014Applicant: Kao CorporationInventors: Chika Suzukamo, Koji Onizawa, Noriko Osawa
-
Publication number: 20140212464Abstract: The present invention describes an oil-in-water emulsion composition for wet-wipes delivering an improved body cleansing performance while providing a gentle and smooth feeling to the user.Type: ApplicationFiled: January 29, 2013Publication date: July 31, 2014Applicant: THE PROCTER & GAMBLE COMPANYInventors: George Endel Deckner, Leeellen Drechsler, Mathias Kurt Herrlein, Ursula Christina Glaser, Randall Glenn Marsh, Antonio Martinez-Campoy, Philip Andrew Sawin
-
Publication number: 20140205659Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 14, 2014Publication date: July 24, 2014Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian Schoenharting, Bemd W. Muller, Joseph R. Robinson
-
Patent number: 8785443Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.Type: GrantFiled: October 14, 2011Date of Patent: July 22, 2014Assignee: XenoPort, Inc.Inventors: Archana Gangakhedkar, Xuedong Dai, Noa Zerangue, Peter A. Virsik
-
Publication number: 20140200272Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 13, 2014Publication date: July 17, 2014Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140199390Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 14, 2014Publication date: July 17, 2014Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140199392Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 14, 2014Publication date: July 17, 2014Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140199388Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 14, 2014Publication date: July 17, 2014Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian Schoenharting, Bernd W. Mueller, Joseph R. Robinson
-
Publication number: 20140199393Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 13, 2014Publication date: July 17, 2014Applicant: FORWARD PHARMA A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140199387Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 14, 2014Publication date: July 17, 2014Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140199386Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 13, 2014Publication date: July 17, 2014Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140200273Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 13, 2014Publication date: July 17, 2014Applicant: FORWARD PHARMA A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Patent number: 8778991Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.Type: GrantFiled: October 14, 2011Date of Patent: July 15, 2014Assignee: XenoPort, Inc.Inventors: Archana Gangakhedkar, Xuedong Dai, Noa Zerangue, Peter A. Virsik
-
Publication number: 20140193495Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 13, 2014Publication date: July 10, 2014Applicant: FORWARD PHARMA A/SInventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
-
Publication number: 20140194427Abstract: Provided is a compound of formula (I): or a pharmaceutically acceptable salt thereof. Also provided is a method of treating, prophylaxis, or amelioration of a disease, comprising administering to a subject in need of treatment for the disease an effective amount of a compound of formula (I) described herein. In one embodiment, the method is a neurodegenerative disease, such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, or Alzheimer's disease.Type: ApplicationFiled: March 7, 2014Publication date: July 10, 2014Applicant: Biogen IDEC MA Inc.Inventor: Jianhua CHAO
-
Publication number: 20140194505Abstract: Disclosed are neuraminidase inhibitor compounds and pharmaceutical compositions with improved bioavailability and/or improved efficacy and methods of treating influenza using the compounds and pharmaceuticals compositions.Type: ApplicationFiled: February 11, 2014Publication date: July 10, 2014Applicant: SineVir Therapeutics LLCInventors: John Hilfinger, Wei Shen
-
Publication number: 20140187631Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprises 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).Type: ApplicationFiled: February 3, 2012Publication date: July 3, 2014Inventors: Richard D. Kpoke, Robert A. Floyd, Rheal Towner
-
Publication number: 20140187632Abstract: The present invention provides a use of a lipid composition for the preparation of a nutritional, pharmaceutical or nutraceutical composition or a functional food, for the prevention and treatment of gastrointestinal diseases and disorders, and for promoting intestinal development, maturation, adaptation and differentiation.Type: ApplicationFiled: December 20, 2013Publication date: July 3, 2014Applicant: ENZYMOTEC LTD.Inventors: Fabiana Bar-Yosef, Gai Ben Dror, Tzafra Cohen, Yael Lifshitz
-
Publication number: 20140179779Abstract: Provided is a compound of formula (I): or a pharmaceutically acceptable salt thereof. Also provided is a method of activating the Nrf2 pathway, comprising contacting cells with a sufficient amount of a compound of formula (I) described herein. Also provided is a method of treating a neurodegenerative disease, comprising administering to a subject in need of treatment for the neurodegenerative disease an effective amount of a compound of formula (I) described herein.Type: ApplicationFiled: December 20, 2013Publication date: June 26, 2014Inventor: Jianhua CHAO
-
Publication number: 20140179777Abstract: A taste-masked liquid composition of docusate includes a docusate salt, povidone, a polyether, and water. Additional ingredients in the composition may include thickeners, sweeteners, flavorants, polyols, preservatives, chelating agents and pH adjusters. Such compositions may be used as taste-masked oral compositions of docusate, and may provide therapeutic effects such as stool-softening.Type: ApplicationFiled: January 18, 2013Publication date: June 26, 2014Inventors: Jelena Djordjevic, Mohammad Rahman
-
Publication number: 20140179778Abstract: Disclosed herein are cocrystals of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, which is a prodrug of methyl hydrogen fumarate.Type: ApplicationFiled: November 5, 2013Publication date: June 26, 2014Applicant: XenoPort, Inc.Inventors: Chen Mao, Scott L. Childs
-
Patent number: 8759354Abstract: Disclosed is a pharmaceutical composition comprising a pyrazine derivative represented by the general formula: [wherein R1 and R2 independently represent a hydrogen atom or a halogen atom; and R3 represents a hydrogen atom or an amino-protecting group] or a salt thereof and at least one neuraminidase inhibitor. The pharmaceutical composition is useful for a treatment including the treatment or prevention of influenza. Also disclosed is a method of using these components in combination. The method is useful for a treatment including the treatment or prevention of influenza.Type: GrantFiled: February 14, 2008Date of Patent: June 24, 2014Assignee: Toyama Chemical Co., Ltd.Inventor: Masako Maekawa
-
Patent number: 8759392Abstract: Methods and compounds useful for inhibiting a phoshpolipase A2 are provided, the methods comprising contacting the phoshpolipase A2 with a compound having the structure A, or pharmaceutically acceptable salts thereof: wherein R1 is H, F, NH2, or COOH; R2 is, H, linear saturated or unsaturated alkyl, alkenyl, or alkynyl; each of R3 and R4 is independently H, linear saturated or unsaturated alkyl, alkenyl, alkynyl, phenyl, or substituted phenyl; R5 is H, (C1-C6) alkyl such as methyl or ethyl; X is aryl or substituted aryl, such as phenyl or a substituted phenyl; and Y is O or S.Type: GrantFiled: July 21, 2009Date of Patent: June 24, 2014Assignee: The Regents of the University of CaliforniaInventors: Edward A. Dennis, George Kokotos, Violetta Constantinou-Kokotou, Samuel David
-
Patent number: 8758743Abstract: A coenzyme Q10-containing composition comprising a coenzyme Q10 and a hydrophilic fatty acid ester of a polyhydric alcohol; a coenzyme Q10-containing composition comprising a coenzyme Q10, a lipophilic fatty acid ester of a polyhydric alcohol and a hydrophilic fatty acid ester of a polyhydric alcohol; and a food or beverage comprising the coenzyme Q10-containing composition as defined above.Type: GrantFiled: January 15, 2004Date of Patent: June 24, 2014Assignee: Taiyo Kagaku Co., Ltd.Inventors: Rumi Yamaguchi, Hiroaki Yamaguchi, Hironobu Nanbu, Lekh Raj Juneja, Nagahiro Yamazaki
-
Patent number: 8759393Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.Type: GrantFiled: March 4, 2011Date of Patent: June 24, 2014Assignee: Biogen Idec International GmbHInventors: Rajendra Kumar Joshi, Hans-Peter Strebel
-
Publication number: 20140171504Abstract: Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (HbF) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce HbF expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (HBB) or an expression control sequence thereof. Pharmaceutical dosage units and dosage regimes for use in the disclosed methods are also provided.Type: ApplicationFiled: December 13, 2013Publication date: June 19, 2014Applicant: Georgia Regents Research Institute, Inc.Inventor: Vadivel Ganapathy